Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Shareholder Meeting (March 2023)
37 slides from Devonian Health's shareholder meeting presentation, Mar 17, 2023
Slide 1: Welcome – Bienvenue: Annual General Meeting of Shareholders
Welcome – Bienvenue Annual General Meeting of Shareholders Quebec City, March 17 2023 TSVx : GSD OTCQB : DVHGF
Slide 2: Cautionary Statements
Cautionary Statements Certain statements contained in this document constitute forward-looking information and forward-looking statements (collectively, “forward-looking statements”) pursuant to the Applicable Securities Regulations. All statements, other than statements of historical fact, containe
Slide 3: Company Overview
Company Overview March 2023 Farm toPharm™ 3
Slide 4: The Life Science Opportunity: Did you know?
The Life Science Opportunity : Did you know ? A. US $2.07 TRILLION1 ➢ The projected revenue of Global Pharmaceutical market by 2028. B. USA and Canada Market Share2,3 ➢ Nearly half of it comes from U.S. (45%) and Canada (2%). C. 21.6 %4 ➢ Represents the net profit margin for the healthcare technolog
Slide 5: Thykamine: Focus on Atopic Dermatitis
THYKAMINE™ : FOCUS ON ATOPIC DERMATITIS Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 5
Slide 6: Global Atopic Dermatitis Market
Global Atopic Dermatitis Market Global Atopic Dermatitis Treatment Market Value, in USD Million, Y-O-Y Growth Rate (2022-2027) 15.78% 14.40% 13.28% 11.99% Y-O-Y Growth Rate 9.48% 10.65% USD Million 11,703.14 14,502.17 16,428.06 18,793.70 21,759.34 12,949.52 2022(E) 2023(F) 2024(F) 2025(F) 2026(F) 20
Slide 7: Atopic Dermatitis Phase 2 Trial - Adult Patient Population
1- Atopic Dermatitis (AD) Phase 2 Trial - Adult Patient Population Setting Stage for Phase 3: Strong clinical results reflecting safety and efficacy forming the basis of future development efforts in dermatology Proportion of patients achieving Primary Endpoint : IGA 0 or 1 AND 2-point Reduction fro
Slide 8: Atopic Dermatitis Phase 2 Trial - Secondary Endpoint
1 Atopic Dermatitis (AD) Phase 2 Trial - Adult Patient Population Setting Stage for Phase 3: Strong clinical results reflecting safety and efficacy form the basis of future development efforts in dermatology Secondary Endpoint : Proportion of patients achieving secondary endpoint : IGA 0 or 1 50.0 4
Slide 9: Atopic Dermatitis Phase 2 Trial - Safety Data
Atopic Dermatitis (AD) Phase 2 Trial - Adult Patient Population 1 Safety Data Incidence of AEs, n (%) that were probably, possibly, or definitely related to study medication (safety population). Thykamine™ Thykamine™ Thykamine™ (PUR 0110) (PUR 0110) (PUR 0110) Severity Adverse event Vehicle (n=40) 0
Slide 10: Thykamine – Best-In-Class Potential – Targeted Pediatric Patients
Thykamine™ – Best-In-Class Potential – Targeted Pediatric Patients Favorable safety profile could uniquely position Thykamine™ within competitive landscape in Mild-to-Moderate Atopic Dermatitis in Pediatric population… Drug Mech of Action Patient Restrictions Adverse Events Use Limitations Age Limit
Slide 11: Thykamine – Best-In-Class Potential vs Corticosteroids
Thykamine™ – Best-In-Class Potential – Targeted Pediatric Patients … including a highly favorable profile vs corticosteroids – the oldest and most widely prescribed drug class for the pediatric patient population Drug Mech of Action Patient Restrictions Adverse Events Use Limitations Age Limitations
Slide 12: Thykamine Pediatric Development Program
Thykamine™ Pediatric Development Program Farm to PharmTM 12
Slide 13: Global Atopic Dermatitis Market Summary
Global Atopic Dermatitis Market Summary Market value (US $ Bn) Global AD Market $ 25.3 Bn AD Drug Treatment Market $ 19.7 Bn AD Topical Drug Market $ 13.3 Bn AD Mild-to-Moderate Market (80.8% of Topical) $ 10.8 Bn AD Pediatric Market (62,4%) $ 6.7 Bn Farm to PharmTM 13
Slide 14: Global Atopic Dermatitis Market by Intensity
Global Atopic Dermatitis Market by Intensity GLOBAL ATOPIC DERMATITISMARKET SHARE RESEARCH AND ANALYSIS BY INTENSITY, 2023-2028 (%) Intensity 2023 2024 2025 2026 2027 2028 Mild 37.09% 37.06% 37.03% 36.99% 36.96% 36.93% > 80% Moderate 43.46% 43.53% 43.61% 43.68% 43.76% 43.83% Severe 19.45% 19.41% 19.
Slide 15: Pediatric Mild-to-Moderate Atopic Dermatitis Treatment Landscape
Pediatric Mild-to-Moderate Atopic Dermatitis Treatment Landscape ▪ Topical Corticosteroids. ▪ Tacrolimus 0.03% • Fear and anxiety regarding treatment with topical • Calcineurin inhibitor. corticosteroids • Use in pediatric ≥2 years. • Topical steroid withdrawal reactions • concerns regarding its imm
Slide 16: Pediatric Mild-to-Moderate Atopic Dermatitis Treatment Landscape
Pediatric Mild-to-Moderate Atopic Dermatitis Treatment Landscape ▪ Patients with atopic dermatitis are at higher risk of multiple autoimmune diseases (1): • Alopecia areata, • Celiac disease, • Crohn’s disease, • Rheumatoid arthritis, • Systematic lupus erythematosus, • Ulcerative colitis ▪ FDA : At
Slide 17: Why should we focus on Pediatric Segment?
Why should we focus on Pediatric Segment? ▪ Not a crowded market ▪ Most treatments available can only be used on alternate basis – none can be used on a continuous basis ▪ Younger patients (<12 years): underserved within this market ▪ Leadership possibility as new therapeutic approach (Botanical Dru
Slide 18: Focus on Pediatric Market Opportunity
Focus on Pediatric Market Opportunity ▪ Target approval in pediatric population with mild-to-moderate AD ▪ Planned protocol for the clinical study ✓ Drug concentration: 0.05%, 0.1%, placebo ✓ Treatment duration 12 weeks: Competition has only 4 / 6 weeks data ✓ Monitoring by a Safety Committee (acces
Slide 19: Radiotherapy Supportive Care
Radiotherapy supportive Care Farm toPharm™
Slide 20: Radiodermatitis: An Unmet Medical Need
Radiodermatitis:(1,2,3) An unmet Medical Need — In North America, Europe and Australia : 50% of patients diagnosed with cancer will receive radiation therapy during their illness • Sarcoma, head & neck, breast, vulvar, anal cancers, prostate etc… — 90% of these patients will develop some degree of r
Slide 21: Radiodermatitis: An Unmet Medical Need
Radiodermatitis : An Unmet Medical Need ▪ Current Therapies (1,2) • Many currently used interventions often based upon anecdotal evidence • No gold standard for prevention/management • No conclusive evidence to endorse any specific intervention ▪ Concept for New Product • Thykamine™ anti-inflammator
Slide 22: Radiodermatitis associated to Radiotherapy
Radiodermatitis associated to Radiotherapy ✓Protocol Completed • Target : Head and Neck Cancer • Sample size : 80 patients • Study completion : 8 -12 Months ✓Once completed: File under Medical Device Regulation Farm to PharmTM 22
Slide 23: Chemotherapy Supportive Care
Chemotherapy Supportive Care Farm to PharmTM 23
Slide 24: Hand & Foot Syndrome Associated To Chemotherapy
Hand & Foot Syndrome Associated To Chemotherapy : An Unmet Medical Need (1,2,3,4,5,6) — Hand & Foot syndrome (HFS), also known as palmoplantar erythrodysesthesia or acral erythema, is a well- documented adverse effect of numerous chemotherapeutic agents. — The most common causes are pegylated liposo
Slide 25: Hand & Foot Syndrome Associated to Chemotherapy
Hand & Foot Syndrome Associated to Chemotherapy: An Unmet Medical Need Current Therapies (1) • Supportive treatments such as topical wound care, elevation, and cold compresses may help to relieve the pain. • Use of systemic corticosteroids, pyridoxine (vitamin B6), blood flow reduction, and, recentl
Slide 26: Hand & Foot Syndrome associated to chemotherapy
Hand & Foot Syndrome associated to chemotherapy ✓Phase 2 Protocol Completed • Target : Breast Cancer • Sample size : 180patients • Study completion : 12 – 18 Months Farm to PharmTM 26
Slide 27: Year in Details 2022/23
2022/23 Year in Details Farm toPharm™ 27
Slide 28: 2022/23 – Supply Chain Disruptions
2022/23 – Supply Chain Disruptions Medicines: why so many stock-outs? Shortages of children's Tylenol, Ventolin, EpiPen, antibiotics or cancer drugs are not due to the pandemic, but to gaps in the supply chain. What can be done to protect the population? Health and science by Valérie Borde — March 1
Slide 29: Devonian - Supply-chain disruptions
Devonian - Supply-chain disruptions I. Supply chain disruptions surfaced in early 2022. ▪ Manufacture of pharmaceutical creams for clinical studies ▪ Contract manufacturers are overwhelmed ▪ It took over 9 months to find and conclude an agreement with a manufacturer (Cambrex) ▪ The selected manufact
Slide 30: 2022/23 Corporate Milestones
2022/23 Corporate Milestones ▪ March 10 - Devonian listed on US Stock Exchange OTCQB under ‘‘DVHGF’’ ▪ August 29 : Executive changes • Sybil Dahan : Chairman of the board of Directors • Pierre Montanaro : President & CEO • Dr Andre Boulet : Chief Scientific Officer ▪ October 6 - Publication of Phase
Slide 31: 2022/23 R&D Milestones
2022/23 R&D Milestones ▪ New article published in International journal of non-communicable diseases: • Thykamine™ potential application for Covid-19 associated inflammation ▪ Finalize protocol for Atopic Dermatitis clinical study • Start Phase 2/3 pediatric study in fall of 2023 ▪ Finalize protocol
Slide 32: 2022/23 R&D Milestones
2022/23 R&D Milestones ▪ Developed new serum formulation with R-Spinasome® currently in stability testing for the anti-ageing Purgenesis™ brand ▪ Developed two new regenerating creams with two different concentrations aimed at Professionals and Consumers: • Lower concentration for Consumers • Higher
Slide 33: 2022/23 Altius Healthcare Inc.
2022/23 Altius Healthcare Inc. ▪ 2022: Executive changes: • P. Montanaro joined as New CEO • S. Dahan retired from her position of President ▪ Jan 2023: Signed a new distribution Agreement: • Authorized generic version of a major GI tract remedy Farm toPharm™ 33
Slide 34: Growth Phase 2023-24
2023-24 Growth Phase Farm toPharm™ 34
Slide 35: 2023/24 Corporate Milestones
2023/24 Corporate Milestones ▪ Currently in discussion with several financing groups to secure required funding. • Due diligence completed with three groups ▪ Finalize selection process to find the ideal BD/M&A Partner: • Initiate BD/M&A initiative to secure a strategic partnership with a Pharma Com
Slide 36: 2023/24 R&D Milestones
2023/24 R&D Milestones ▪ Initiate Phase 2/3 clinical trial in Atopic Dermatitis pediatric population planned for Fall 2023 ▪ Initiate pivotal study in radiodermatitis late fall 2023. ▪ Initiate Phase 2 clinical study in Hand & Foot Syndrome in Q1/2024 ▪ Finalize Cell-Base Assay for Thykamine QA/QP p
Slide 37: Thank you! Merci!
Thank you ! Merci ! 360 Des Entrepreneurs, Montmagny, Quebec, Canada G5V 4T1 TSXv : GSD OTCQB: DVHGF
Devonian Health Group — Shareholder Meeting (March 2023) on 6ix